The combination of high-dose proton therapy with concurrent chemotherapy improved non-hematologic acute toxicity and late acute toxicity in patients with stage III non–small cell lung cancer, according to a study.
Patients were evaluated at least once every week during treatment; at 6 weeks after completing proton therapy; every 3 months for the first 2 years after finishing treatment; and every 6 months thereafter. Median follow-up was 19.7 months.
No patient experienced grade-5 toxicity and only five patients (11.4%) developed chemotherapy-related grade-4 toxicities — two instances of weight loss and three cases of hemoglobin. Read more…
Advertisements
Leave a Reply